



Patent Application  
Attorney Docket No.PC9923B

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents P. O. Box 1450, Alexandria, VA 22313-1450 on this 30<sup>th</sup> day of September 2003.

By

*Irene Grantham*  
(Signature of person mailing)  
Irene Grantham

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Mary T. Am Ende, et al. :

APPLICATION NO.: 10/611,586 : Examiner: To Be Assigned

FILING DATE: June 30, 2003 : Group Art Unit: To Be Assigned

TITLE: SUSTAINED RELEASE FORMULATIONS :  
FOR GROWTH HORMONE  
SECRETAGOGUES

Hon. Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).




Patent Application  
Attorney Docket No. PC9923B

A prompt and favorable response is earnestly solicited.

Date: 30 SEPTEMBER 2003  
Pfizer Inc.  
Patent Department, MS 8260-1611  
Eastern Point Road  
Groton, Connecticut 06340  
(860) 715-6645

Respectfully submitted,

  
John A. Wichtowski  
Attorney for Applicant(s)  
Reg. No. 48,032

OCT 07 2003  
 TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)									ATTY. DOCKET NO. PC9923B			SERIAL NO. 10/611,586		
									APPLICANT Mary T. Am Ende, et al.					
									FILING DATE June 30, 2003			GROUP To B Assign d		
<b>U.S. PATENT DOCUMENTS</b>														
EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	US	5	7	2	3	4	4	1	3/3/98	Higley, et al.	514	12		
	US	5	7	2	3	6	1	6	3/3/98	Houghton, et al.	546	18		
	US	5	7	7	3	4	1	1	6/30/98	Wells, et al.	514	11		
	US	5	7	7	3	4	4	1	6/30/98	Hipskind, et al.	514	253		
	US	5	8	4	0	3	3	1	11/24/98	Cauter, et al.	424	464		
	US	5	9	1	9	7	7	7	7/9/99	Hansen, et al.	514	183		
	US	5	9	4	5	4	1	2	8/31/99	Fuh, et al.	514	176		
	US	5	9	4	8	7	5	7	9/7/99	Sommer, et al.	514	12		
	US	6	1	0	7	3	0	6	8/22/00	Carpino, et al.	514	303		
	US	6	2	2	8	3	9	8	5/8/01	Devane, et al.	424	484		
<b>FOREIGN PATENT DOCUMENTS</b>														
DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	WO	9	4	1	3	6	9	6 ✓	6/23/94	International	C07K	5/02		
	WO	9	5	3	0	4	2	2 ✓	11/16/95	International	A61K	31/71		
	WO	9	7	1	5	1	9	1 ✓	5/1/97	International	A01N	43/38		
	WO	9	7	2	4	3	6	9 ✓	7/10/97	International	C07K	5/06		
	WO	9	7	4	4	0	4	2 ✓	11/27/97	International	A61K	31/505		
	WO	9	8	5	8	9	4	7 ✓	12/30/98	International	C07K	5/023		
	WO	9	8	5	8	9	4	8 ✓	12/30/98	International	C07K	5/023		
	WO	9	9	0	1	1	1	3 ✓	1/14/99	International	A61K	9/48		
	WO	9	9	0	1	1	2	0 ✓	1/14/99	International	A61K	31/135		
	WO	9	9	0	1	1	2	1 ✓	1/14/99	International	A61K	31/135		
	WO	9	9	0	1	1	2	2 ✓	1/14/99	International	A61K	31/135		
	WO	9	9	2	4	0	6	2 ✓	5/20/99	International	A61K	38/30		
	WO	9	9	6	5	4	8	6 ✓	12/23/99	International	A61K	31/435		
	WO	9	9	6	5	4	8	8 ✓	12/23/99	International	A61K	31/44		



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)										ATTY. DOCKET NO. PC9923B					SERIAL NO. 10/611,586									
										APPLICANT Mary T. Am Ende, et al.														
										FILING DATE June 30, 2003					GROUP To Be Assigned									
	WO	0	0	1	2	0	4	7	3/9/00	International	A61K													
	WO	0	2	1	7	9	1	8	3/7/02	Internationals	A61K	31/445												
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)																								
			Bercu, et al., "Sex Differences in Growth Hormone (GH) Secretion by Rats Administered GH-Releasing Hexapeptide", <u>Endocrinology</u> 129(5), pp. 2592-2598 (1991) ✓																					
			Hartman, et al., "Temporal structure of in vivo growth hormone secretory events in human", <u>The American Physiological Society</u> , pp. E101-E110 (1991) ✓																					
			Huhn, et al., "Twenty-Four-Hour Growth Hormone (GH)-Releasing Peptide (GHRP) Infusion Enhances Pulsatile GH Secretion and Specifically Attenuates the Response to a Subsequent GHRP Bolus", <u>Journal of Clinical Endocrinology</u> 76(5), pp. 1202-1207 (1993) ✓																					
			Gevers, et al., "Growth, Growth Hormone (GH)-Binding Protein, and GH Receptors Are Differentially Regulated by Peak and Trough Components of the GH Secretory Pattern in the Rat", <u>Endocrinology</u> , pp. 1013-1018 (1996) ✓																					
			Clark, et al., "Paradoxical Growth-Promoting Effect Patterned Infusions of Somatostatin", <u>Endocrinology</u> , pp. 2675-2682 (1988) ✓																					
			Clark, et al., "Intravenous growth hormone: growth responses to patterned infusions in hypophysectomized rats", <u>J. Endocr.</u> 104, pp. 53-61 (1985) ✓																					
			Robinson, "Chronopharmacology of growth hormone and related peptides", <u>Advanced Drug Delivery Reviews</u> 6, pp. 57-82 (1991) ✓																					
			Smith, et al., "Peptidomimetic Regulation of Growth Hormone Secretion", <u>Endocrine Reviews</u> 18(5), pp. 621-645 (1997) ✓																					
			Van Den Berghe, et al., "The Somatotrophic Axis in Critical Illness: Effect of Continuous Growth Hormone (GH)-Releasing Hormone and GH-Releasing Peptide-2- Infusion", <u>Journal of Clinical Endocrinology and Metabolism</u> 82(2), pp. 590-599 (1997) ✓																					
EXAMINER																								
DATE CONSIDERED																								
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.																								